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Abstract 
New pyridopyrimidine derivatives were defined using a novel HTS in silico docking method 
(FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key 
role in nucleotide biosynthesis of Mycobacterium tuberculosis (Mtb). Top hit molecules were 
assayed in vitro for their antimycobacterial effect on Mtb H37Rv culture. In order to enhance the 
cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a 
nanoparticle type delivery system (polylactide-co-glycolide, PLGA) was applied. The conjugate had 
relevant in vitro antitubercular activity with low in vitro and in vivo toxicity. In a Mtb H37Rv 
infected guinea pig model the in vivo efficacy of orally administrated PLGA encapsulated 
compound was proved: animals maintained a constant weight gain and no external clinical signs of 
tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found 
negative for Mtb, and diagnostic autopsy showed that no significant malformations on the tissues 
occurred. 
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1. INTRODUCTION 
 
In silico docking methods and structure-based drug design are useful bioinformatics tools for 
identifying new agents against tuberculosis. In our previous study 
1
, a newly developed FRIGATE 
docking algorithm 
2
 was utilized for a virtual screen of several million small molecules against the 
species-specific surface loop of Mtb DUTPase (EC 3.6.1.23; Rv2697) enzyme 
3, 4
. As a result, we 
reported the identification of 10 new compounds, active against Mtb H37Rv in vitro. The lowest 
minimal inhibitory concentration (MIC) was measured for TB8 compound (1 µg/mL, 3.7 µM), a 
pyridopyrimidine derivative. To optimize the structure of TB8 compound, more than 100 
derivatives were synthesized, in vitro evaluated and the structure-activity relationship was analyzed. 
One of the derivatives, TB820 molecule (4-oxo-2-(pyrrolidin-1-yl)-pyrido[1,2-a]pyrimidine-3-
carbaldehyde) was chosen in this study for further modification in order to improve its therapeutic 
efficacy by using advanced drug delivery system (DDS).  
Targeted delivery of antitubercular drugs into macrophages, which provide the intracellular survival 
of the mycobacteria, has crucial pharmaceutical benefits. The phagocytic uptake process of 
macrophages is highly efficient due to the expression of specific receptors such as the IgG receptor 
and complement receptors 
5
. DDS can be engineered to achieve enhanced cellular uptake and 
bioavailability, controlled drug release and reduced side effects. In this paper we report the design 
of a new type of advanced DDS, where the antitubercular agent is conjugated to a tuftsin peptide 
derivative and encapsulated into PLGA nanoparticles. Tuftsin is a natural phagocytosis stimulating 
peptide produced by enzymatic cleavage of the Fc-domain of the heavy chain of IgG. During the 
past decade, a new group of sequential oligopeptide carriers has been developed in our laboratory: 
oligotuftsin derivatives consisting of a pentapeptide unit TKPKG 
6, 7
. In this study, the TKPKG 
peptide was elongated with palmitic acid to enhance the lipophilicity, membrane affinity and 
encapsulation efficacy. Nanoencapsulation into lactic and glycolic acid (PLGA) copolymers is an 
efficient method for sustained controlled release and intensively explored for antitubercular therapy 
8
. These biodegradable and biocompatible polymer-based nanoparticles have the ability to 
essentially modify the biodistribution of an active compound and the release rate can be controlled 
by the size and composition of the particles 
9
. PLGA is approved by the US Food and Drug 
Administration (FDA) for clinical use and it can be utilized in oral formulation 
10
. 
Synthesis and characteristics of peptide-conjugated and PLGA encapsulated TB820 is described in 
this work. In vitro antitubercular efficacy of the conjugate is compared to its cytotoxicity and 
hemolytic activity. Furthermore, in vivo chemotherapeutic effect of the orally administered PLGA-
pT820 compound in a guinea pig infectious model is presented. 
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2. MATERIALS AND METHODS 
 
2.1. Synthesis and characterization of PLGA encapsulated pal-T5(TB820)2 
The TB820 compound was conjugated to a palmitoylated tuftsin derivative. First protected tuftsin 
(TKPKG, T5) was produced manually by solid-phase peptide synthesis using Boc/Bzl strategy. 
Palmitic acid was coupled to the N-terminus of the peptide. The N

-Fmoc protecting groups of the 
side chain of Lys residues were selectively removed and free amino groups were reacted with Boc-
aminooxyacetic acid.  After Boc deprotection, peptide was removed from the resin with liquid HF 
in the presence of scavengers. Palmitoylated aminooxi-peptide was then allowed to react with the 
TB820 compound in solution and the precipitated conjugate was filtered and purified. Final product 
pal-T5(TB820)2 (pT820) was characterized by analytical RP-HPLC, ESI-MS and amino acid 
analysis.  
 
PLGA nanoparticles were prepared by the nanoprecipitation (solvent exchange) method, detailed 
previously 
11
. Briefly, PLGA and pT820 conjugate were dissolved in acetone and added dropwise to 
an aqueous solution of Pluronic 12700. The resulting nanoparticle suspension was centrifuged, 
purified by dialysis and freeze-dried. Drug content of the lyophilized powder was determined by 
amino acid analysis.  
 
2.2. In vitro tests 
In vitro antitubercular activity of the compound was determined against Mycobacterium 
tuberculosis H37Rv (ATCC 27294) and multiresistant M. tuberculosis (MDR A8) by serial dilution 
method in Sula semi-synthetic medium. The minimal inhibitory concentration (MIC) was 
determined after incubation at 37
o
C for 28 days. The activity of the tested compounds was 
confirmed using colony forming unit (CFU) enumeration by subculturing from the Sula medium 
onto drug-free Löwensten-Jensen solid medium (37oC, 28 days).  
 
In vitro cytotoxicity was evaluated on human peripheral blood mononuclear cells (PBMC), 
prepared from peripheral blood of healthy volunteers using Ficoll-Hypaque density gradient 
centrifugation method. The pT820 conjugate was added to the cells to give 0.5 M – 200 M final 
concentration. Cells were incubated at 37
o
C for 4 hours, then cell viability was tested using MTT 
(3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. 
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In vitro hemolytic activity of pT820 was determined on human erythrocytes. Red blood cell 
suspension was incubated with the compounds (0.5 M – 200 M final concentration) for 4 hours 
at 37
o
C and after centrifugation, the absorbance of the supernatant was measured at λ=450 nm. 
 
2.3. In vivo evaluation 
Inbred, female guinea pigs aged 6 weeks at weight 400-500 g were housed four per cage and 
allowed free access to water and to standard pellet diet. All animal experiments were approved by 
the Hungarian Scientific Ethical Committee on Animal Experimentation (No: 22.1/3720/003/2009). 
 
To study the in vivo toxicity, animals were administered orally twice a week with 50 mg/kg bw of 
PLGA-pT820 (n = 3 for the treatment group). To monitor the side effects, changes in body weight 
were determined weekly and after 7 weeks of administration, animals were euthanized and 
diagnostic autopsy was evaluated. 
 
In vivo antitubercular effect of the PLGA-pT820 compound was evaluated on Mtb infected guinea 
pigs (n = 6 for treatment and 6 for control group). First, guinea pigs were infected with Mtb H37Rv 
suspension by intramuscular injection. Infection was followed by sacrificing one animal each week 
and performing histopathological analysis from the organs. Chemotherapy was started 3 weeks after 
infection. PLGA-pT820 compound (50 mg/kg bw) was suspended in 1 mL sterile water and 
administrated orally twice a week. Control animals were administered of 1 mL sterile water with the 
same frequency. After 12 weeks of chemotherapy, animals were euthanized by ketamine (40 mg/kg 
bw) and dexmedetomidine (Dexdomitor, 0.5 mg/kg bw).  
To count the number of bacteria in the organs, a portion of lung, spleen, liver and kidney were 
resected and homogenized in Sula media. 1:1000 dilutions of the homogenates were plated onto 
Löwenstein-Jensen solid media and after 8 weeks of incubation CFU was enumerated. For 
histopathological analysis, lung, spleen, liver, kidney, inguinal lymph nodes and heart muscle of 
each animal were removed and fixed in 8% neutral buffered formalin for 24 hours at room 
temperature. Tissue specimens were dehydrated in a series of ethanol and xylene baths and 
embedded in paraffin wax. Sections (3-4 μm) were stained with haematoxylin and eosin (HE.). For 
in situ visualization of the acid-fast bacilli Ziehl–Neelsen (ZN) staining method was applied on 
similarly pre-treated sections.  
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3. RESULTS AND DISCUSSION 
 
Palmitoylated tuftsin derivative was used as a carrier for the TB820 compound. Chemical structure 
and homogeneity of the conjugate was proved by mass spectrometry (Mmo(calculated) = 1362.8; 
Mmo(found) = 1362.8), analytical RP-HPLC and amino acid analysis. Structure and mass spectra of 
the pT820 conjugate is given in FIGURE 1. 
 
FIGURE 1. Chemical structure of the pT820 conjugate. The N-terminal of TKPKG pentapeptide is 
palmitoylated, the C-terminus is amidated. The TB820 compound is coupled to the side chains of 
the two lysine amino acids through oxime bond. High resolution mass spectrum shows the isotopic 
distribution of the pT820 molecule.  
 
The pT820 conjugate was encapsulated into PLGA nanoparticles by nanoprecipitation method. The 
encapsulation efficacy was up to 83%. The drug content of the PLGA-pT820 nanoparticles was 
20.2%.   
 
3.1. In Vitro Antitubercular effect, cytotoxicity and hemolytic activity 
Antitubercular effect of the compounds was measured against Mtb H37Rv strain. The MIC value of 
the TB820 molecule was 1 µg/mL (4.1 µM), while the MIC value of the pT820 conjugate was 5 
µg/mL (3.7 µM). From this result we can conclude that the chemical modification of the TB820 
molecule did not influence its antimicrobial efficacy. The antitubercular effect of the compounds 
was also tested on multiresistant Mtb (MDR A8) strain. The MIC value was 1 µg/mL (4.1 µM) for 
the TB820 molecule and 10 µg/mL (7.4 µM) for the pT820 conjugate. Before in vivo experiments, 
we assayed the cytotoxicity and hemolytic activity in vitro. We found that the pT820 conjugate was 
not cytotoxic to human PBMC and to human erythrocytes even at the highest concentration (IC50 > 
200 µM; HC50 > 200 µM). 
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3.2. In Vivo toxicology and chemotherapeutic effect of PLGA-pT820 
To monitor the toxicity of PLGA-pT820, 3 guinea pigs were administered orally twice a week with 
a dose of 50 mg/kg bw. During the experiment animals maintained a constant weight gain and no 
symptoms, related to compound toxicity were observed. After 7 weeks of administration of PLGA-
pT820, animals were euthanized and diagnostic autopsy proved that no significant malformations 
on the tissues occurred.  
 
To study the chemotherapeutic effect, guinea pigs were infected intramuscularly with Mtb H37Rv 
suspension. After 3 weeks of incubation, the animals were randomly divided into two groups. Six 
guinea pigs were treated orally with PLGA-pT820 (50 mg/kg bw, twice a week for a period of 12 
weeks).  Six animals receiving sterile water with the same frequency were employed as controls. As 
illustrated in FIGURE 2/A, all PLGA-pT820 treated guinea pigs steadily gained weight throughout 
the whole experiment. No death occurred and no external clinical signs of tuberculosis were 
observed. Furthermore, the plated tissue homogenates were bacteria free after 8 weeks of incubation 
(FIGURE 2/B). In comparison, 3 infected animals died at the 13
rd
, 14
th
 and 19
th
 week of the 
experiment (FIGURE 2/C). Other signs, related to tuberculosis, such as weight loss, scuffed fur or 
lethargy, were also observed in three other cases. These external clinical signs were proved by 
mycobacterial CFU, detected in spleen, lung, liver and kidney homogenates as presented in 
FIGURE 2/D.  
 
FIGURE 2. Chemotherapy of Mtb infected guinea pigs. PLGA-pT820 treated animals gained 
weight steadily (A) and no mycobacterial colonies were observed in the tissue homogenates (B). In 
panel C, the weight gain of infected but untreated control animals is presented (* indicates the death 
of an animal). To prove TB infection, CFU was determined from the plated tissue homogenates (D), 
(+++ : confluent colonies; ++ : innumerable colonies, but not confluent; + : 50-100 colonies; - : no 
colonies were observed). 
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The histopathological analysis of tissues of Mtb infected guinea pigs clearly demonstrates the 
formation of typical tuberculotic lesions, e.g. formation of multiple epitheloid granulomas in the 
lymph nodes, lungs, liver and spleen of the infected animals, as a result of type IV, TH1 mediated 
hypersensitivity reaction. Ziehl-Neelsen staining demonstrated the acid-fast bacteria in the 
cytoplasm of the epitheloid cells, or in the multinucleated giant cells (FIGURE 3). 
 
 
FIGURE 3. Representative histological spectrum of TB using intramuscular infection model of 
guinea pigs. A typical tubercle is observed (panel A, spleen section), where the arrow indicates the 
central necrosis, which is surrounded by epitheloid macrophages. In panel B the deep purple 
precipitations represent multifocal calcification in the necrotic areas, whereas in panel C the arrows 
point at multinucleated Langhans type giant cells as a result of epitheloid macrophage fusion. In 
panel D, rod-shaped Ziehl-Neelsen stained Mycobacterium is shown. Panel B, C and D are lymph 
node sections. Panel A, B, C: Sections were stained with HE. 200× Bar, 50µm; D: ZN staining, 
1000× Bar, 10µm. 
 
As a summary of this study we can conclude that a new type of peptide based drug delivery system 
was applied for the TB820 molecule with relevant chemotherapeutic efficacy against experimental 
tuberculosis. Palmitoylated tuftsin peptide conjugate of TB820 found to be effective against 
susceptible and multiresistant Mtb strains with a relatively high in vitro selectivity (IC50 and HC50 
was more than 50-times higher than MIC). The pT820 conjugate was entrapped into PLGA 
nanoparticles with high encapsulation efficacy. The PLGA-pT820 compound was not toxic to 
guinea pigs at the therapeutic concentration. Guinea pigs were infected with virulent Mtb H37Rv and 
treated with PLGA-pT820. Untreated control animals show numerous severe lesions with extensive 
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parenchymal involvement. These signs of infection were characterized by the evidence of necrosis 
with intralesional mineralization, thus reflecting progression of the disease. In contrast, PLGA-pT5i 
treated animals had considerably decreased inflammation and minimal granulomatous involvement.  
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